Innovation in Pharma: the Highs and Lows of the Current Healthcare economy

While the likely premium price of upcoming genetic and cell-based therapies challenges traditional NHS funding mechanisms, the continuing influx of biosmilars is driving down the cost of biologics.
The high cost of new medicines is a well-worn topic of debate. But current innovation in pharma is impacting both the higher and lower ends of the healthcare economy, creating new challenges for clinicians and payers and causing both new hope and, potentially, confusion for patients.
Read more here.

Related Posts

Leave a Reply

Your email address will not be published. Required fields are marked